Neha Korde

5.9k total citations
124 papers, 2.1k citations indexed

About

Neha Korde is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Neha Korde has authored 124 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Hematology, 52 papers in Molecular Biology and 41 papers in Oncology. Recurrent topics in Neha Korde's work include Multiple Myeloma Research and Treatments (108 papers), Protein Degradation and Inhibitors (31 papers) and Cancer Treatment and Pharmacology (16 papers). Neha Korde is often cited by papers focused on Multiple Myeloma Research and Treatments (108 papers), Protein Degradation and Inhibitors (31 papers) and Cancer Treatment and Pharmacology (16 papers). Neha Korde collaborates with scholars based in United States, Sweden and Iceland. Neha Korde's co-authors include Ola Landgren, Sigurður Y. Kristinsson, Sham Mailankody, Ingemar Turesson, Alexander M. Lesokhin, Hani Hassoun, Paul A. Janmey, Mark Roschewski, Dickran Kazandjian and Magnus Björkholm and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Neha Korde

113 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Neha Korde United States	26	1.4k	1.1k	772	327	260	124	2.1k
Camille N. Abboud United States	27	1.6k 1.1×	810 0.8×	783 1.0×	478 1.5×	558 2.1×	109	2.7k
Cristina Papayannidis Italy	26	1.4k 1.0×	1.0k 1.0×	882 1.1×	508 1.6×	207 0.8×	160	2.7k
Tara L. Lin United States	25	1.5k 1.0×	1.2k 1.1×	571 0.7×	519 1.6×	192 0.7×	160	2.4k
Patrick Wuchter Germany	27	900 0.6×	575 0.5×	692 0.9×	581 1.8×	280 1.1×	119	2.1k
Benjamin Van Camp Belgium	23	1.1k 0.7×	743 0.7×	657 0.9×	250 0.8×	256 1.0×	65	2.0k
Edgar Jost Germany	23	551 0.4×	1.0k 0.9×	392 0.5×	318 1.0×	314 1.2×	100	1.8k
XG Zhang China	16	1.2k 0.8×	892 0.8×	964 1.2×	211 0.6×	586 2.3×	40	2.2k
Naoki Hosen Japan	28	659 0.5×	1.7k 1.6×	791 1.0×	204 0.6×	871 3.4×	111	2.9k
Anupriya Agarwal United States	28	1.7k 1.2×	1.4k 1.3×	497 0.6×	1.2k 3.6×	537 2.1×	85	3.1k
Matthias Kotzsch Germany	30	607 0.4×	1.1k 1.0×	486 0.6×	286 0.9×	227 0.9×	75	2.3k

Countries citing papers authored by Neha Korde

Since Specialization

Citations

This map shows the geographic impact of Neha Korde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neha Korde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neha Korde more than expected).

Fields of papers citing papers by Neha Korde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neha Korde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neha Korde. The network helps show where Neha Korde may publish in the future.

Co-authorship network of co-authors of Neha Korde

This figure shows the co-authorship network connecting the top 25 collaborators of Neha Korde. A scholar is included among the top collaborators of Neha Korde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neha Korde. Neha Korde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kazandjian, Dickran, Benjamin Diamond, Romanos Sklavenitis‐Pistofidis, et al.. (2024). Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma. Clinical Cancer Research. 30(19). 4482–4490. 5 indexed citations

Desai, Pinkal, Sagar Lonial, Amanda F. Cashen, et al.. (2024). A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clinical Cancer Research. 30(21). 4844–4855. 15 indexed citations

Voorhees, Peter M., Anita D’Souza, Alfred Chung, et al.. (2024). Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7531–7531. 8 indexed citations

Laracy, Justin, Nina Cohen, Elizabeth Robilotti, et al.. (2023). Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients. Haematologica. 108(11). 3058–3067. 6 indexed citations

Derkach, Andriy, Billel Gasmi, Theodora Anagnostou, et al.. (2023). T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis. Blood. 142(Supplement 1). 3326–3326. 1 indexed citations

Weisel, Katja, Anita D’Souza, David D. Hurd, et al.. (2023). P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere. 7(S3). e0036307–e0036307. 1 indexed citations

Firestone, Ross, Andriy Derkach, Kylee Maclachlan, et al.. (2023). P-486 Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S307–S308. 1 indexed citations

Hultcrantz, Malin, Even H. Rustad, Venkata Yellapantula, et al.. (2022). Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research. 28(10). 2160–2166. 1 indexed citations

Korde, Neha, et al.. (2022). Examining health related quality of life outcomes in multiple myeloma: Past and future perspectives. Seminars in Oncology. 49(1). 94–102. 3 indexed citations

10.

Shah, Urvi A., Andriy Derkach, Sham Mailankody, et al.. (2021). A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study. Blood. 138(Supplement 1). 4759–4759.

11.

Korde, Neha & Saad Z. Usmani. (2021). Cross Fire: Daratumumab-Based Therapies Are Standard of Care in Newly Diagnosed Multiple Myeloma. Hematology/Oncology and Stem Cell Therapy. 16(2). 117–123. 1 indexed citations

12.

Beedie, Shaunna, Cindy H. Chau, David Venzon, et al.. (2019). Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. Scientific Reports. 9(1). 14884–14884. 5 indexed citations

13.

Kazandjian, Dickran, Elizabeth Hill, Malin Hultcrantz, et al.. (2019). Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Genetics Research. 4 indexed citations

14.

Pianko, Matthew J., Jessica Flynn, Sean M. Devlin, et al.. (2018). Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience. Blood. 132(Supplement 1). 5591–5591.

15.

Þórðardóttir, Maríanna, Ebba K. Lindqvist, Sigrún H. Lund, et al.. (2018). Dietary intake is associated with risk of multiple myeloma and its precursor disease. PLoS ONE. 13(11). e0206047–e0206047. 21 indexed citations

16.

Carlsten, Mattias, Neha Korde, Ritesh R. Kotecha, et al.. (2016). Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma. Clinical Cancer Research. 22(21). 5211–5222. 134 indexed citations

17.

Devlin, Sean M., Jill Vanak, Heather Landau, et al.. (2016). Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transplantation. 51(4). 546–552. 38 indexed citations

18.

Wang, Weixin, Adriana Zingone, Azam Ghafoor, et al.. (2015). Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. Journal of Molecular Diagnostics. 17(6). 669–678. 36 indexed citations

19.

McShane, Charlene M., Liam Murray, Ola Landgren, et al.. (2014). Prior Autoimmune Disease and Risk of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Systematic Review. Cancer Epidemiology Biomarkers & Prevention. 23(2). 332–342. 45 indexed citations

20.

Korde, Neha, Robert Bucki, Jennifer J. Pastore, et al.. (2002). Purification of salmon thrombin and its potential as an alternative to mammalian thrombins in fibrin sealants. Thrombosis Research. 107(5). 245–254. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact